Stomach Cancer Treatment Market Size, Share and Trends 2025 to 2034

The global stomach cancer treatment market size is accounted at USD 6.08 billion in 2025 and is forecasted to hit around USD 17.60 billion by 2034, representing a healthy CAGR of 12.54% from 2025 to 2034. The Asia Pacific market size was estimated at USD 3.02 billion in 2024 and is expanding at a CAGR of 12.65% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : 02 Jan 2025
  • Report Code : 5409
  • Category : Healthcare

Stomach Cancer Treatment Market Size and Forecast 2025 to 2034

The global stomach cancer treatment market size was evaluated at USD 5.40 billion in 2024 and is predicted to reach around USD 17.60 billion by 2034, expanding at a CAGR of 12.54% from 2025 to 2034. The demand for the stomach cancer treatment market is increasing due to the rise in global cancer incidences. This promotes the adoption of technologies that can help in providing therapies to patients.

Stomach Cancer Treatment Market Size 2025 to 2034

Stomach Cancer Treatment Market Key Takeaways

  • Asia Pacific dominated the global market with the largest market share of 56% in 2024.
  • Middle East and Africa are anticipated to grow at the highest CAGR during the forecast period.
  • By treatment type, the targeted therapy segment contributed the highest market share of 40% in 2024.
  • By treatment type, the immunotherapy segment is projected to grow at the fastest CAGR of 17.03% in the future years.
  • By disease indication, the gastric cancer/gastroesophageal junction cancer segment captured the biggest market share of 85% in 2024.
  • By disease indication, the gastrointestinal stromal tumors segment is expected to grow significantly during the forecast period.
  • By drug class, the PD-1/PD-L1 inhibitors segment is expected to grow at the highest CAGR during the forecast period.
  • By route of administration, the injectable treatment segment generated the major market share of 90% in 2024.
  • By route of administration, the oral treatment segment is expected to grow at the fastest CAGR of 18.83% during the forecast period.

What is the role of AI in the stomach cancer treatment market?

Technologies like artificial intelligence (AI) and machine learning (ML) are playing an impactful role in the healthcare sector, including the stomach cancer treatment market. The major role of AI in these treatments is to analyze medical imaging and convey medical abnormalities that can enhance treatment outcomes. AI also analyses the data and helps in creating personalized treatment plans. The use of AI in R&D activities is also beneficial in boosting the analyzing process, as the tools can improve the process by analyzing chemical compounds in the research process. The rising investments in these tools are also anticipated to create more precision in AI-assisted surgery outcomes.

Asia Pacific Stomach Cancer Treatment Market Size and Growth 2025 to 2034

The Asia Pacific stomach cancer treatment market size was exhibited at USD 3.02 billion in 2024 and is projected to be worth around USD 9.86 billion by 2034, growing at a CAGR of 12.65% from 2025 to 2034.

Asia Pacific Stomach Cancer Treatment Market Size 2025 to 2034

Asia Pacific dominated the global stomach cancer treatment market in 2024. The dominance of the region is attributed to the higher patient rates in countries like China and Japan. For instance, China reported 246,550 stomach cancer cases in men in 2022 which calculates almost around 10% of the cancer disease.

The increasing health conditions have led to the growth in the healthcare infrastructure which is providing business opportunities in the region. Additionally, governments in the region are also implementing policies which promote health screening for individuals.

Stomach Cancer Treatment Market Share, By Region, 2024 (%)

Middle East and Africa is anticipated to grow at the highest CAGR in the stomach cancer treatment market during the forecast period of 2025 to 2034. The growth of the region is attributed to the increasing awareness regarding stomach cancer which boosts the healthcare infrastructure in countries like UAE and Saudi Arabia. Additionally, the changing dietary habits of this population may increase the risk of these conditions in the coming years.

Market Overview

Stomach cancer treatment deals with the therapies and other medical procedures that are applied to manage and cure cancer disease that originates from the stomach. Stomach cancer, also known as gastric cancer, develops due to chronic inflammation in the stomach, which can also lead to intestinal metaplasia. The stomach cancer treatment market deals with the manufacturing and distribution of treatments and therapies applied to cure patients. The market is witnessing significant demand due to the increasing demand for various treatments like surgery, chemotherapy, radiation therapy, and many others. The World Cancer Research Fund states that stomach cancer is the 5th most common cancer worldwide.

Stomach Cancer Treatment Market Growth Factors

  • The rise in global cancer incidences due to many reasons, like changing lifestyles and other conditions, has been playing a crucial role in the development of the stomach cancer treatment market.
  • The growth in treatments like immunotherapy is playing a crucial role in enhancing treatment outcomes, contributing to market growth.
  • The increasing credibility of biosimilars stands out as a major growth factor as they provide cost-effective solutions in cancer treatment. 
  • The dietary changes of individuals also contribute to the growth of cancer incidences due to unhealthy habits like smoking and alcohol consumption.

Market Scope

Report Coverage Details
Market Size by 2024 USD 5.40 Billion
Market Size in 2025 USD 6.08 Billion
Market Size in 2034 USD 17.60 Billion
Market Growth Rate from 2025 to 2034 CAGR of 12.54%
Leading Region Asia Pacific
Fastest Growing Region Middle East and Africa
Base Year 2024
Forecast Period 2025 to 2034
Segments Covered Treatment Type, Disease Indication, Route of Administration, Drug Class, and Regions
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Market Dynamics 

Driver

Increasing healthcare expenditure in developing countries

The rapid urbanization in developing countries has led to the need for improvisation across various industries, including healthcare. Multiple factors like changing lifestyles in these regions are increasing the disease-prone population. This leads to increasing developments in the healthcare facilities within the regions, including cancer treatments. The rising disposable incomes in countries like China, Mexico, Thailand, and others increase the affordability of these people to afford these treatments. Technological advancements in therapies are being adopted to enhance the patients' experience.

Rise in the aging population

According to the American Cancer Society, the average of people diagnosed with stomach cancer is 68, and around 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. The stomach cancer treatment market grows due to the increasing changes in the human body of elderly people that make them more prone to these diseases. Additionally, these populations also have other health conditions like diabetes and other CADs, which increases the complications in the treatment procedures and leads to the demand for more efficient and result-oriented results.

Restraint

Higher costs of advanced therapies

Technological evolution has marked significant growth in the majority of the developed and developing regions, but there are still some factors that tend to affect market growth. The stomach cancer treatment market has also managed to adopt advanced therapies due to its outcomes, which can be financially unaffordable for underdeveloped regions. This often leads to medical tourism, which also stands as a restraining factor for low-income patients.

Opportunities

Rising awareness among individuals

The rise of new media, i.e., the means of mass communication using the internet, has been playing a vital role in increasing health awareness among individuals, especially adults. The stomach cancer treatment market stands out with numerous opportunities as the patients are opting for early diagnosis and treatment after witnessing symptoms regarding these diseases, which are weight loss, stomach pain, and many more. This demand is leading to significant advancements in the health screening processes, which can help individuals with early detection and treatments that can lead to successful outcomes.

Government policies and regulatory support

The rising incidence of cancer has caught the attention of the health ministries of various governments, which are attracting significant funding for the development. The stomach cancer treatment market has been growing significantly due to the support of various governments. For example, the Indian government provides funds for poor cancer patients under ‘Rashtriya Arogya Nidhi.’ Additionally, many governments have availed free screening programs for people to come up and undergo these tests for early detection. The rising drug approval rate for these conditions will also help in providing medications for poor people at lower costs.

Treatment Type Insights

The targeted therapy segment marked its dominance over the market in 2024. The treatment includes the use of drugs to identify cancer cells and control their growth according to their needs. The stomach cancer treatment market has been witnessing significant demand due to the use of these therapies for a longer period, as they are considered to be safe and efficient. The outcomes of these therapies are effective due to the presence of HER2-targeted drugs. Additionally, these therapies can be applied to various stages of the disease, which increases its availability in the majority of the regions. The widespread demand for these drugs is also leading to more innovation in these therapies for more result-oriented treatments.

The immunotherapy segment is anticipated to grow rapidly in the market from 2025 to 2034. The treatment works to improve the immune system and identify and destroy cancer cells. The growth of these therapies is attributed to the rapid innovation in advanced solutions that can provide long-term benefits to patients in some cases. The expansion of the treatment options also makes these therapies more reliant on these diseases. The stomach cancer treatment market is anticipated to grow more efficiently due to the increasing research practices for enhancement in these services.

Disease Indication Insights

The gastric cancer/gastroesophageal junction cancer segment stood dominant over the market in 2024. This cancer develops where the esophagus meets the stomach. The stomach cancer treatment market is growing due to the increasing number of individuals who smoke. Unhealthy dietary habits also contribute to the increasing number of these cases. The changing lifestyles of individuals have established proper treatment options for these conditions, which generates more opportunities in the healthcare industry. Additionally, the increasing regulatory support for the promotion of health screening contributes to market growth.

Stomach Cancer Treatment Market Share, By Disease Indication, 2024 (%)

The gastrointestinal stromal tumors segment is expected to grow significantly during the forecast period of 2025 to 2034. This is a rare cancer disease that is formed in the tissues of the gastrointestinal (GI) tract. The main cause of the disease is genetic mutation, which makes it rare. The stomach cancer treatment market is growing efficiently due to the rapid advancements in therapies like imatinib, sunitinib, and many more, which focus on treatment outcomes. The professionals are also focusing on research to develop more accurate treatment procedures to cure these diseases. The rising advancements will also contribute to improving the credibility of these treatments.

Drug Class Insights

The PD-1/PD-L1 inhibitors segment is expected to grow at the highest CAGR during the forecast period of 2025 to 2034. These are part of the immunotherapy drugs which are used to treat cancer. The growth in immunotherapy is also leading towards the growth of these drugs, contributing to the growth of the stomach cancer treatment market. The rising drug approval rates are also anticipated to drive more demand in the upcoming years.

Route of Administration Insights

The injectable treatment segment dominated the global market in 2024. The segment refers to the administration of drugs directly into the muscles and bloodstreams, which are most effective due to their quick absorption. This makes it more popular in the advanced cancer stages like chemotherapy, where the drugs are injected through injections. It is a worldwide formula used in these treatments that contributes to the growth of the stomach cancer treatment market.

Stomach Cancer Treatment Market Share, By Route of Administration , 2024 (%)

The oral treatment segment will grow rapidly in the market during the forecast period of 2025 to 2034. The administration of the drugs is done with the help of capsules, pills, and other liquid medications, which are gaining popularity due to the changing patient preferences for more convenient treatment options. This is leading to the growth of many medications that can help in cancer treatment. The stomach cancer treatment market is gaining popularity due to the innovation of these oral treatment options, which are considered to be more cost-effective as compared to the injectables.

Stomach Cancer Treatment Market Companies

Stomach Cancer Treatment Companies
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • CELLTRION INC.
  • Samsung Bioepis
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company

Latest Announcements by Industry Leaders 

  • In August 2024, HUTCHMED's CEO, Weiguo Su, announced that fruquintinib combined with paclitaxel shows promise as a future treatment for gastric cancer, and further investigation into its potential will continue.

Recent Developments

  • In August 2024, Vanderbilt University Medical Center announced receiving a USD 2.5 million Department of Defense grant to fund clinical trials testing two potential treatments for stomach cancer prevention, including pyrvinium, an existing drug, and low-dose trametinib, to develop personalized preventive strategies.
  • In August 2024, the FDA approved trastuzumab deruxtecan (Enhertu) for use in any advanced HER2-positive solid cancer, marking it as the first tumor-agnostic antibody-drug conjugate for this indication.

Segments Covered in the Report

By Treatment Type 

  • Standard Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By Disease Indication

  • Gastric Cancer/Gastroesophageal Junction Cancer
  • Gastrointestinal Stromal Tumors

By Route of Administration

  • Oral
  • Injectable

By Drug Class

  • PD-1/PD-L1 Inhibitors
  • HER2 Antagonists
  • VEGFR Antagonists
  • Others

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global stomach cancer treatment market size is expected to grow from USD 5.40 billion in 2024 to USD 17.60 billion by 2034.

The stomach cancer treatment market is anticipated to grow at a CAGR of 12.54% between 2025 and 2034.

The major players operating in the stomach cancer treatment market are Mylan N.V., Teva Pharmaceutical Industries Ltd., CELLTRION INC., Samsung Bioepis, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, and Others.

The driving factors of the stomach cancer treatment market are the increasing due to the rise in global cancer incidences also Increasing healthcare expenditure in developing countries.

Asia Pacific region will lead the global stomach cancer treatment market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Meet the Team

Rohan Patil is one such expert who is helping shape the future of healthcare market insights with his deep industry knowledge and forward-thinking approach. Rohan holds a BSc. in Biotechnology and an MBA in Marketing, a combination that allows him to blend scientific understanding with strategic business acumen. With over 5 years of experience in the market research industry, Rohan

Learn more about Rohan Patil

With over 14 years of experience, Aditi is the powerhouse responsible for reviewing every piece of data and content that passes through our research pipeline. She is not just an expert—she’s the linchpin that ensures the accuracy, relevance, and clarity of the insights we deliver. Aditi’s broad expertise spans multiple sectors, with a keen focus on ICT, automotive, and various other cross-domain industries.

Learn more about Aditi Shivarkar

Related Reports